Recent Updates
Recently added Catalysts

MP-376

Phase 3

Cystic Fibrosis | Small molecule | Respiratory |Amgen Inc.|Last Updated: Dec 13, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedPLACEBO_CONTROLLEDDMCBiomarker
Total Trials3
Total Enrollment349
FDA Designations
No designations recorded
Clinical Trials (3)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01270347Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) PatientsPHASE3 COMPLETED 282Jan 1, 2011Jun 1, 2013Dec 13, 2024130 United States, France +4
NCT00840333"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"PHASE1 COMPLETED 27Apr 1, 2009Dec 1, 2009Dec 4, 20246 United States
NCT00503490Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic FibrosisPHASE1 COMPLETED 40Jun 1, 2007Dec 1, 2007Dec 4, 202414 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
From start of study until end of the study (up to 168 days)

An AE was defined as any unfavorable or unintended sign, symptom, or disease temporally associated with the use of a Study Drug, whether or not considered related to the Study Drug. An AE could potentially be a new disease, any untoward event, or an exacerbation of a pre-existing condition. AEs included, but were not limited to: Any symptom not previously reported by the patient (medical history) An exacerbation of a pre-existing illness An increase in frequency or intensity of a pre-existing episodic event or condition A condition first detected or diagnosed after Study Drug administration even though the condition may have been present before the start of the study Overdose of Study Drug

Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (FEV1)
Baseline, day 28

FEV1 was the volume of air exhaled in first second of a forced expiration as measured by spirometer. Least squares (LS) mean and standard error (SE) were determined from an analysis of covariance model with terms for treatment, region (US, non-US), and age (12 to 18 years, \> 18 years), and Baseline FEV1 (\< 55%, . 55%).

Safety and Tolerability of MP-376 administered for 14 days to CF patients ages 6-16
21 days
Safety and tolerability of MP-376 administered twice a day for 14 days
14 days
Secondary Endpoints
Percent Change From Baseline in Average Expired Flow Over the Middle Half of The FVC Maneuver (FEF25-75)
Baseline, day 28
Percent Change From Baseline in Forced Vital Capacity (FVC)
Baseline, day 28
Number of Participants in Each Category of Relative Change in Percent Predicted FEV1
Day 28
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AeroquinEXPERIMENTALAeroquin, Inhaled Levofloxacin (MP-376)
TISACTIVE_COMPARATORTobramycin Inhalation solution (TIS) \[TOBI® Novartis Pharmaceuticals\]
1EXPERIMENTALCF PATIENTS 6-11 YEARS OF AGE
2EXPERIMENTALCF PATIENTS 12-16 YEARS OF AGE
Interventions
NameTypeDescription
MP-376 (Levofloxacin Solution for Inhalation)DRUGMP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
TIS (Tobramycin Inhalation Solution)DRUGTobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
placeboDRUGBID
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites130

Inclusion Criteria (selected): * \> 12 years of age * Confirmed Diagnosis of Cystic Fibrosis * Positive sputum culture for P. aeruginosa within the past 12 months * Patients are able to elicit an FEV1 \>/= 25% but \</= 85% of predicted value at screening * Have received at least 3 courses of inhale...

Countries:United StatesFranceGermanyIrelandIsraelUnited Kingdom
Unlock Eligibility Criteria